T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients
Vincent Poindron(Inserm), Thierry Martin(Western Infirmary), Aurélien Guffroy(Hôpitaux Universitaires de Strasbourg), Anne‐Sophie Korganow(Inserm), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Laurent Arnaud(Université Libre de Bruxelles), Soraya El Ghannudi(Université de Strasbourg), Philippe Germain(Université de Strasbourg), Pierre-Edouard Gavand(Université de Strasbourg), Afshin Gangi(King's College Hospital), Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), Matthieu Canuet(Université de Strasbourg)
Cited by 37
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432